Literature DB >> 19412103

Adherence to osteoporosis treatments: room for improvement.

Amy H Warriner1, Jeffrey R Curtis.   

Abstract

PURPOSE OF REVIEW: Osteoporosis is a growing problem worldwide, with the greatest burden resulting from fractures. Currently available are several treatment options that are effective in reducing fracture risk. Patient adherence to these medications is required for benefit to be seen. Yet, similar to other chronic asymptomatic diseases, adherence to osteoporosis therapies is poor. The reasons for suboptimal adherence are multiple but include fear of possible side effects, dosing requirements, and an unwillingness to take a medication for a 'silent' disease. Poor adherence leads to reduced effectiveness, increased morbidity, and increased medical costs. RECENT
FINDINGS: Efforts to improve adherence to osteoporosis treatments are ongoing. The first obstacle in improving adherence to osteoporosis treatments is determining causes of poor adherence. Despite several identifiable causes, improving adherence is difficult. Passive patient education with printed information alone does not appear very effective. Physician-patient interaction, including discussion of bone mineral density results, discussion of osteoporosis medication benefits, and feedback of treatment effects, may be more effective.
SUMMARY: Improved patient education, better tolerated and less frequently dosed medications, and more healthcare provider-patient interaction may improve adherence and lead to greater fracture reduction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412103      PMCID: PMC2913429          DOI: 10.1097/BOR.0b013e32832c6aa4

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  45 in total

1.  Noncompliance may cause half of antihypertensive drug "failures".

Authors:  J Stephenson
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

3.  Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study.

Authors:  M Guilera; M Fuentes; M Grifols; J Ferrer; X Badia
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

4.  Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

Authors:  Ronald Emkey; William Koltun; Kathleen Beusterien; Larry Seidman; Alan Kivitz; Vipul Devas; Daiva Masanauskaite
Journal:  Curr Med Res Opin       Date:  2005-12       Impact factor: 2.580

Review 5.  Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.

Authors:  Joyce A Cramer; Stuart Silverman
Journal:  Am J Med       Date:  2006-04       Impact factor: 4.965

6.  Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.

Authors:  Bradi B Granger; Karl Swedberg; Inger Ekman; Christopher B Granger; Bertil Olofsson; John J V McMurray; Salim Yusuf; Eric L Michelson; Marc A Pfeffer
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

7.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

8.  Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.

Authors:  Joyce A Cramer; Mayur M Amonkar; Ansgar Hebborn; Roy Altman
Journal:  Curr Med Res Opin       Date:  2005-09       Impact factor: 2.580

9.  Persistence with weekly alendronate therapy among postmenopausal women.

Authors:  J C Lo; A R Pressman; M A Omar; B Ettinger
Journal:  Osteoporos Int       Date:  2006-04-12       Impact factor: 4.507

10.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

Authors:  A Cooper; J Drake; E Brankin
Journal:  Int J Clin Pract       Date:  2006-06-19       Impact factor: 2.503

View more
  20 in total

Review 1.  Measuring and improving adherence to osteoporosis pharmacotherapy.

Authors:  Suzanne M Cadarette; Andrea M Burden
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

2.  Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women?

Authors:  S L Brennan; W D Leslie; L M Lix
Journal:  Osteoporos Int       Date:  2013-08-02       Impact factor: 4.507

3.  Hip fracture prevention with a multifactorial educational program in elderly community-dwelling Finnish women.

Authors:  T Pekkarinen; E Löyttyniemi; M Välimäki
Journal:  Osteoporos Int       Date:  2013-05-08       Impact factor: 4.507

4.  Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results.

Authors:  D Brask-Lindemann; S M Cadarette; P Eskildsen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

Review 5.  Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Emma D Deeks; Sohita Dhillon
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

Review 6.  Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Marit D Moen; Susan J Keam
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

7.  Improving treatment adherence in patients with rheumatologic disease.

Authors:  Sofia de Achaval; Maria E Suarez-Almazor
Journal:  J Musculoskelet Med       Date:  2010-10-12

8.  Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.

Authors:  Y Zhao; S S Johnston; D M Smith; D McMorrow; K Krohn; J Krege
Journal:  Osteoporos Int       Date:  2013-03-26       Impact factor: 4.507

9.  Counseling patients on facial volume replacement and adherence with posttreatment instructions.

Authors:  Doris Day
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

10.  Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile.

Authors:  J D Ringe; P Farahmand
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.